FDA

Five things for pharma marketers to know: Monday, September 25, 2017

Five things for pharma marketers to know: Monday, September 25, 2017

By

The FDA declines to approve an opioid and a treatment for rheumatoid arthritis; KKR closes WebMD buyout; 60% of teens have received the HPV vaccine

Five things for pharma marketers to know: Friday, September 22, 2017

Five things for pharma marketers to know: Friday, September 22, 2017

By

Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts

The FDA issues its second enforcement letter of 2017

The FDA issues its second enforcement letter of 2017

By

The OPDP has only issued two letters in 2017, compared to 11 last year.

Five things for pharma marketers to know: Wednesday, August 30, 2017

Five things for pharma marketers to know: Wednesday, August 30, 2017

By

Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info

PhRMA criticizes the FDA's research into drug advertising and promotion

PhRMA criticizes the FDA's research into drug advertising and promotion

By

The lobbying group said it's unclear what the agency's goal is with this research and how it promotes public health.

Five things for pharma marketers to know: Wednesday, August 16, 2017

Five things for pharma marketers to know: Wednesday, August 16, 2017

By

Gottlieb criticizes drugmakers for 'gaming the system' on generics; investors ignore Trump's pharma criticism; docs are more supportive of single payer

Questions About Promotion Prompt Marketers to Develop Code of Ethics

Questions About Promotion Prompt Marketers to Develop Code of Ethics

That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.

Bill to allow imported drugs from Canada aims to create competition

Bill to allow imported drugs from Canada aims to create competition

By

The Congressional Budget Office says that Sanders' bill would save the U.S. federal government nearly $7 billion over the next decade.

Five things for pharma marketers to know: Wednesday, August 9, 2017

Five things for pharma marketers to know: Wednesday, August 9, 2017

By

The FDA on pace for record generic drug approvals; CVS Health CEO doubts Amazon's entrance to pharmacy market; Sanofi to develop cancer immunotherapy

Five things for pharma marketers to know: Tuesday, August 8, 2017

Five things for pharma marketers to know: Tuesday, August 8, 2017

By

A shorter list of risks in TV ads helps consumer comprehension; medical-school choice affects prescribing patterns; reps often show docs the same info

Five things for pharma marketers to know: Friday, August 4, 2017

Five things for pharma marketers to know: Friday, August 4, 2017

By

AbbVie's new HCV drug is cheaper than Gilead's Harvoni; Lilly's experimental migraine drugs beats placebo; Fitbit to launch smartwatch

Five things for pharma marketers to know: Thursday, August 3, 2017

Five things for pharma marketers to know: Thursday, August 3, 2017

By

FDA committee votes against J&J arthritis drug; scientists successfully edit genes; Shire mulls ADHD spin off

How Do Docs Learn About New Drugs? TV, Of Course

How Do Docs Learn About New Drugs? TV, Of Course

If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.

Five things for pharma marketers to know: Wednesday, August 2, 2017

Five things for pharma marketers to know: Wednesday, August 2, 2017

By

Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement

Five things for pharma marketers to know: Tuesday, August 1, 2017

Five things for pharma marketers to know: Tuesday, August 1, 2017

By

Express Scripts removes 64 branded drugs from 2018 formulary; wearable market can regain momentum, analysts say; FDA accepts Herceptin biosimilars for review

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Tuesday, July 25, 2017

Five things for pharma marketers to know: Tuesday, July 25, 2017

By

Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review

Five things for pharma marketers to know: Friday, July 21, 2017

Five things for pharma marketers to know: Friday, July 21, 2017

By

The FDA to study whether linking to risk information affects patient recall; patients view docs who take industry payments as less honest; Mallinckrodt ups political donations

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Thursday, July 13, 2017

Five things for pharma marketers to know: Thursday, July 13, 2017

By

AstraZeneca CEO reportedly moving to Teva; the FDA reverses on approval for Amicus drug; Merck names winners of Alexa challenge

Novartis' CAR-T therapy gets nod from FDA committee

Novartis' CAR-T therapy gets nod from FDA committee

By

The drugmaker is one step closer to a potential approval of its experimental cancer treatment.

Five things for pharma marketers to know: Monday, July 10, 2017

Five things for pharma marketers to know: Monday, July 10, 2017

By

Gottlieb calls for new opioid training for docs; FDA committee to examine Novartis' CAR-T therapy; no Viagra ads expected during NFL season

Five things for pharma marketers to know: Friday, July 7, 2017

Five things for pharma marketers to know: Friday, July 7, 2017

By

Drug ads on mobile are not providing enough risk info; rare-disease drugmakers are concerned about healthcare bill; volume of opioid prescriptions drops

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

By

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Five things for pharma marketers to know: Friday, June 30, 2017

Five things for pharma marketers to know: Friday, June 30, 2017

By

The FDA plans to review orphan drug backlog; drugmaker supported charity helped patients pay for donor's drugs; low dose Xarelto gets Priority Review

Five things for pharma marketers to know: Thursday, June 29, 2017

Five things for pharma marketers to know: Thursday, June 29, 2017

By

Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition

Five things for pharma marketers to know: Tuesday, June 27, 2017

Five things for pharma marketers to know: Tuesday, June 27, 2017

By

Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate

Five things for pharma marketers to know: Monday, June 26, 2017

Five things for pharma marketers to know: Monday, June 26, 2017

By

The performance of generic drugs is not always guaranteed; the FDA approves a new blood thinner; Gottlieb wants rejection letters public

Five things for pharma marketers to know: Thursday, June 22, 2017

Five things for pharma marketers to know: Thursday, June 22, 2017

By

The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement

The FDA attempts to understand how disclosures affect drug ads

The FDA attempts to understand how disclosures affect drug ads

By

The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.